AstraZeneca has raised its revenue guidance for the full year after strong sales of its Evusheld Covid-19 antibody treatment and drugs to treat cancer and rare diseases.
在Evusheld新冠抗體治療劑和治療癌癥和罕見疾病的藥物銷售強勁后，阿斯利康上調了全年營收指引。
您已閱讀7%（218字），剩余93%（3107字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。